TY - JOUR
T1 - BNCT for primary synovial sarcoma
AU - Fujimoto, Takuya
AU - Suzuki, Minoru
AU - Kuratsu, Shigeyuki
AU - Fujita, Ikuo
AU - Morishita, Masayuki
AU - Sudo, Tamotsu
AU - Sakuma, Toshiko
AU - Nakamatsu, Yuta
AU - Sakurai, Yoshinori
AU - Takata, Takushi
AU - Tamari, Yuki
AU - Tanaka, Hiroki
AU - Masunaga, Shin ichiro
AU - Kinashi, Yuko
AU - Kondo, Natsuko
AU - Sakakibara, Shunsuke
AU - Igaki, Hiroshi
AU - Andoh, Tooru
AU - Sakamoto, Setsu
AU - Kawamoto, Teruya
AU - Watabe, Tadashi
AU - Hara, Hitomi
AU - Fukase, Naomasa
AU - Kawakami, Yohei
AU - Matsumoto, Tomoyuki
AU - Akisue, Toshihiro
AU - Ono, Koji
AU - Ichikawa, Hideki
AU - Kuroda, Ryosuke
AU - Hirose, Takanori
N1 - Publisher Copyright:
© 2020
PY - 2021/3
Y1 - 2021/3
N2 - Synovial sarcoma is a rare tumor requiring new treatment methods. A 46-year-old woman with primary monophasic synovial sarcoma in the left thigh involving the sciatic nerve, declining surgery because of potential dysfunction of the affected limbs, received two courses of BNCT. The tumor thus reduced was completely resected with no subsequent recurrence. The patient is now able to walk unassisted, and no local recurrence has been observed, demonstrating the applicability of BNCT as adjuvant therapy for synovial sarcoma. Further study and analysis with more experience accumulation are needed to confirm the real impact of BNCT efficacy for its application to synovial sarcoma.
AB - Synovial sarcoma is a rare tumor requiring new treatment methods. A 46-year-old woman with primary monophasic synovial sarcoma in the left thigh involving the sciatic nerve, declining surgery because of potential dysfunction of the affected limbs, received two courses of BNCT. The tumor thus reduced was completely resected with no subsequent recurrence. The patient is now able to walk unassisted, and no local recurrence has been observed, demonstrating the applicability of BNCT as adjuvant therapy for synovial sarcoma. Further study and analysis with more experience accumulation are needed to confirm the real impact of BNCT efficacy for its application to synovial sarcoma.
KW - 4-borono-2-F-fluoro-L-phenylalanine positron emission tomography/computed tomography
KW - Adjuvant therapy
KW - Biphasic subtype
KW - Boron neutron capture therapy (BNCT)
KW - Clinical treatment
KW - F-fluorodeoxyglucose positron emission tomography/computed tomography
KW - Ki-67
KW - L-type amino acid transporter 1
KW - Monophasic subtype
KW - Primary
KW - Synovial sarcoma
KW - p-borono-L-phenylalanine (BPA)
UR - http://www.scopus.com/inward/record.url?scp=85099138227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099138227&partnerID=8YFLogxK
U2 - 10.1016/j.apradiso.2020.109407
DO - 10.1016/j.apradiso.2020.109407
M3 - Article
C2 - 33444907
AN - SCOPUS:85099138227
SN - 0969-8043
VL - 169
JO - Applied Radiation and Isotopes
JF - Applied Radiation and Isotopes
M1 - 109407
ER -